We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
-1.36%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.32B
AUM Growth
-$280M
Cap. Flow
-$198M
Cap. Flow %
-15.04%
Top 10 Hldgs %
17.04%
Holding
1,626
New
448
Increased
346
Reduced
313
Closed
483

Sector Composition

Rank Sector Weight
1 Technology 13.2%
2 Healthcare 10.48%
3 Consumer Discretionary 9.93%
4 Financials 7.26%
5 Communication Services 6.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASML icon
526
ASML
ASML
$666B
$480K 0.04%
724
-1,370
-65% -$997K
PWR icon
527
Quanta Services
PWR
$99.4B
$480K 0.04%
1,887
+1,237
+190% +$357K
VAL icon
528
Valaris
VAL
$5.94B
$477K 0.04%
12,157
+5,250
+76% +$225K
TSLL icon
529
CALL
Direxion Daily TSLA Bull 2X ETF
TSLL
$3.32B
$476K 0.04%
+50,000
New +$924K
TSLA icon
530
PUT
Tesla
TSLA
$1.31T
$466K 0.04%
1,800
-42,200
-96% -$14.1M
EEM icon
531
iShares MSCI Emerging Markets ETF
EEM
$29.8B
$466K 0.04%
10,666
-42,692
-80% -$1.85M
ASML icon
532
PUT
ASML
ASML
$666B
$464K 0.04%
+700
New +$509K
SIMO icon
533
Silicon Motion
SIMO
$7.82B
$463K 0.04%
9,165
-2,244
-20% -$121K
NE icon
534
Noble Corp
NE
$6.95B
$458K 0.03%
+19,341
New +$554K
PLD icon
535
CALL
Prologis
PLD
$132B
$458K 0.03%
4,100
+1,700
+71% +$197K
CKPT
536
DELISTED
Checkpoint Therapeutics
CKPT
$457K 0.03%
+113,081
New +$377K
NKTR icon
537
Nektar Therapeutics
NKTR
$2.53B
$456K 0.03%
44,677
+32,449
+265% +$424K
M icon
538
Macy's
M
$6.55B
$455K 0.03%
36,231
+363
+1% +$5.27K
CVX icon
539
Chevron
CVX
$382B
$455K 0.03%
2,720
+213
+8% +$33.3K
ITW icon
540
Illinois Tool Works
ITW
$83.9B
$453K 0.03%
+1,828
New +$470K
MTD icon
541
Mettler-Toledo International
MTD
$28.6B
$452K 0.03%
383
+136
+55% +$174K
PFXF icon
542
VanEck Preferred Securities ex Financials ETF
PFXF
$2.45B
$451K 0.03%
+26,917
New +$465K
XLE icon
543
State Street Energy Select Sector SPDR ETF
XLE
$39.3B
$450K 0.03%
9,628
QFIN icon
544
Qfin Holdings
QFIN
$1.59B
$450K 0.03%
+10,010
New +$414K
ACCD
545
DELISTED
Accolade Inc
ACCD
$448K 0.03%
64,229
+52,751
+460% +$353K
VRSN icon
546
VeriSign
VRSN
$26.5B
$448K 0.03%
+1,765
New +$401K
ARVN icon
547
Arvinas
ARVN
$588M
$447K 0.03%
63,740
-1,660
-3% -$26K
UPBD icon
548
Upbound Group
UPBD
$1.12B
$447K 0.03%
18,649
+9,248
+98% +$254K
PGR icon
549
Progressive
PGR
$124B
$445K 0.03%
1,571
-2,203
-58% -$576K
GPCR icon
550
Structure Therapeutics
GPCR
$3.82B
$444K 0.03%
25,628
-6,372
-20% -$156K

Similar funds

Prelude Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Prelude Capital Management held 1,626 positions worth $1.32B, down 18% from $1.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Prelude Capital Management withdrew a net $198M in Q1 2025, closing 483 positions and reducing 313 holdings. Its most notable exit was Smartsheet Inc., an estimated $14M position sold in full.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Prelude Capital Management opened a new position in Intra-Cellular Therapies Inc. worth $10.4M.

  • Prelude Capital Management's largest Q1 2025 buy was Intra-Cellular Therapies Inc.: 79,142 shares worth $10.4M.
  • Prelude Capital Management added most to Alphabet (Google) Class A in Q1 2025, an estimated $9.7M increase.
  • Prelude Capital Management's biggest Q1 2025 reduction was NVIDIA, cutting an estimated $9.36M.
  • Prelude Capital Management fully exited Smartsheet Inc. in Q1 2025, selling an estimated $14M.
  • Prelude Capital Management's ten largest holdings make up 17% of its $1.32B portfolio in Q1 2025.
  • Prelude Capital Management opened 448 new positions and closed 483 in Q1 2025.
  • Prelude Capital Management's portfolio value fell 18% quarter-over-quarter to $1.32B.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.